CEPH Message Board - Msg: 6627056

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (827)	12/1/1998 11:09:00 AM
From: Wally	Read Replies (2) of 998

Richard: I don't think we have much of an argument between us. Myotrophin is not a cure nor was it ballyhooed as a cure. It is perhaps no more than a weak aid to those suffering from this horrendous disease and maybe worthless - we don't know for sure, and Cephalon's primitive presentation added a major cloud of confusion and doubt. There is a possibility that Myotrophin is a better answer (however faint the praise) than what's currently FDA approved for treatment. If a 3rd trial proves that Myotrophin is relatively ineffective, the drug may still be approved. In regards to proving effectiveness, you are 100% right when you say "pitching won't change that." Cephalon has relied on Dog and Pony shows over good data. The FDA doesn't like to be bullied and such tactics by Cephalon have (IMO) hurt them well beyond any failings of the drug itself. So my hope is this - Cephalon, having been humbled by the FDA has learned an expensive lesson. If there is any clinical value to Myotrophin, perhaps this time Cephalon will bother to find out for sure. They can ill-afford to keep playing with an empty hand. It works sometimes in poker, but not with the FDA. Wally

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next